Regeneron Strikes Deal With Genentech To Market Eylea
Regeneron Pharmaceuticals Inc. has partially settled its patent litigation in New York against Genentech Inc., securing a licensing agreement in order to market Eylea, a treatment for macular degeneration, the company...To view the full article, register now.
Already a subscriber? Click here to view full article